A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

M. G. Bernengo, F. Vanaclocha, M. Duvic, T. Kuzel, F. Kerdel, L. Pinter-Brown, A. Bosly, C. Okada, D. Breneman, P. L. Zinzani, J. Becker, L. Hughey, M. Ardaiz, J. Zain, L. Zhang, S. Hirawat, G. Laird, D. Johnson, H. M. Prince

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)44-45
Number of pages2
JournalHaematologica Meeting Reports
Volume2
Issue number5
StatePublished - Oct 27 2008

ASJC Scopus subject areas

  • Hematology

Cite this

Bernengo, M. G., Vanaclocha, F., Duvic, M., Kuzel, T., Kerdel, F., Pinter-Brown, L., Bosly, A., Okada, C., Breneman, D., Zinzani, P. L., Becker, J., Hughey, L., Ardaiz, M., Zain, J., Zhang, L., Hirawat, S., Laird, G., Johnson, D., & Prince, H. M. (2008). A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. Haematologica Meeting Reports, 2(5), 44-45.